Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel
A M
AM
Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Cambridge 02139.
Moratalla
R
R
Quinn
B
B
DeLanney
L E
LE
Irwin
I
I
Langston
J W
JW
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001345:Autoradiography; D001931:Brain Mapping; D002421:Caudate Nucleus / Q000187:drug effects / Q000473:pathology; D003342:Corpus Striatum / Q000187:drug effects* / Q000473:pathology; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D007279:Injections, Subcutaneous; D008454:Mazindol / Q000493:pharmacokinetics; D009434:Neural Pathways / Q000187:drug effects / Q000473:pathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000473:pathology; D011699:Putamen / Q000187:drug effects / Q000473:pathology; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000648:ultrastructure; D012453:Saimiri; D013378:Substantia Nigra / Q000187:drug effects* / Q000473:pathology
D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008454:Mazindol; D004298:Dopamine